Public health issues with Candida auris in COVID-19 patients
- PMID: 34909239
- PMCID: PMC8661744
- DOI: 10.1002/wmh3.472
Public health issues with Candida auris in COVID-19 patients
Abstract
The ongoing pandemic of coronavirus disease 2019 (COVID-19) has overwhelmed a number of medical facilities as well as a few entire health-care systems. A novel issue co-incident with the expeditious deployment of specialty care units for COVID-19 inpatients is the worldwide epidemic of Candida auris infections. Since its first identification and classification in Japan in 2009, it has spread globally. This threat was predicted as C. auris has a high mortality rate, cryptic fomite spread, frequent misidentification since conventional methods do not detect it, and multidrug-resistance. Since the April 2020 warning at the start of the COVID-19 pandemic in the United States, C. auris has been delineated as an increasingly consequential source of significant nosocomial infections, emphasizing the added hazard of C. auris to COVID-19 inpatients, particularly those in intensive care units.
Keywords: COVID‐19; Candida auris; nosocomial infections.
© 2021 Policy Studies Organization.
Conflict of interest statement
The authors declare that there are no conflict of interests.
References
-
- de Almeida, J. N., Jr. , Francisco, E. C. , Hagen, F. , Brandão, I. B. , Pereira, F. M. , Presta Dias, P. H. , de Miranda Costa, M. M. , de Souza Jordão, R. T. , de Groot, T. , & Colombo, A. L. (2021). Emergence of Candida auris in Brazil in a COVID‐19 Intensive Care Unit. Journal of Fungi (Basel), 7(3), 220–220. 10.3390/jof7030220 - DOI - PMC - PubMed
-
- Borman, A. M. , Fraser, M. , & Johnson, E. M. (2021). CHROMagar™ Candida Plus: A novel chromogenic agar that permits the rapid identification of Candida auris. Medical Mycology, 59(3), 253–258. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous